(Press-News.org) JACKSONVILLE, Fla. -- Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical trials, believe they know why dasatinib failed -- and what to do about it.
In the online issue of Molecular Oncology, investigators report finding that dasatinib inhibits proteins that promote cancer growth as expected but also suppresses proteins that protect against cancer.
The findings suggest that pretesting patient glioblastoma biopsies will help identify who may respond well to dasatinib and who should avoid using the drug, says the study's senior author, Panos Z. Anastasiadis, Ph.D., chair of the Department of Cancer Biology at Mayo Clinic in Florida.
Dasatinib is a general Src-family kinase (SFK) inhibitor. It shuts down all members of the Src family of protein kinases, which are believed to activate proteins that essentially give tumors "legs" upon which to crawl through tissue to seek blood nutrients.
In the study, the investigators teased apart dasatinib's effect on individual Src family members -- Src, Fyn, Yes and Lyn -- using laboratory glioblastoma cell lines and mouse models of the brain cancer.
In the cell lines, inhibiting Src, Fyn and Yes generally reduced growth and migration. So did Lyn, but to a lesser degree.
But, there were significant differences in mice, depending on which Src family member was experimentally inhibited. Mice with glioblastoma tumors lacking functioning Src or Fyn showed no difference in survival, compared to untreated mice. In contrast, inhibiting Yes in mice increased survival, while inhibiting Lyn resulted in shorter survival and accelerated tumor growth.
"These findings were very surprising to us for two reasons," Dr. Anastasiadis says. "One is the difference between lab and animal findings. The other is that, together with the bad, dasatinib inhibited the good, as well."
"Yes promotes cancer growth, so it should be inhibited," he says. "Unexpectedly though, Lyn protects against cancer growth, and, so, it should not be deactivated by use of dasatinib."
Researchers found that not all human tumors express all members of the Src family, and that expression of Yes and Lyn differed among tumors.
The research team is examining tumor biopsies from the patients who participated in Mayo Clinic's clinical trial testing the use of dasatinib combined with bevacizumab (Avastin), an agent that restricts blood flow to tumors. They will match expression of Lyn and Yes with clinical outcomes.
"We hope these results will affirm our conclusion that patients with high levels of Lyn should not be treated with dasatinib," says Dr. Anastasiadis. "Instead, dasatinib may prove to work well in select patients whose tumors express Yes, but not Lyn.
"The last thing we want to do is target both the good and the bad with dasatinib," says Dr. Anastasiadis. "In the long run, developing a drug that targets Yes, but has no effect on Lyn could prove a much more effective therapy for gliomas."
INFORMATION:
Study co-authors are Laura Lewis-Tuffin, Ph.D.; Ryan Feathers; Priya Hari; Nisha Durand; and Zhimin Li, Ph.D., from Mayo Clinic's Florida campus; Katie Bakken; Brett Carlson; Mark Schroeder; and Jann Sarkaria, M.D., from Mayo Clinic's Minnesota campus; and Fausto Rodriguez, M.D., from Johns Hopkins Hospital in Baltimore.
The study was supported by National Institutes of Health grants R01 NS069753 and R21 NS070117.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit mayoclinic.com or newsnetwork.mayoclinic.org.
In tough economic times, parents financially favor daughters over sons, according to researchers at the Carlson School of Management and Rutgers Business School. Their study, forthcoming in the Journal of Consumer Research, found participants preferred to enroll a daughter rather than a son in beneficial programs, preferred to give a U.S. Treasury bond to a daughter rather than a son, and bequeathed a greater share of their assets to female offspring in their will when they perceived economic conditions to be poor.
"Almost all parents say that they don't favor one of ...
A specific type of talk therapy dispensed in the developing world to orphans and other vulnerable children who experienced trauma such as sexual and domestic abuse showed dramatic results, despite being administered by workers with little education, new research shows.
The findings, from a group of researchers led by the Johns Hopkins Bloomberg School of Public Health, suggest that young people from poor nations can benefit from mental health treatment, even when health professionals do not provide it. Untreated childhood trauma, the researchers say, is linked to skills ...
Scientists at the University of Malta and the Institut de Génétique Moléculaire de Montpellier (CNRS/Université de Montpellier) have shown that fruit flies and brewer's yeast can reveal clues about the cause of Spinal Muscular Atrophy (SMA), the most common genetic killer of infants.
SMA is a devastating neuromuscular disorder that robs children of their ability to walk, eat, or breathe. Mostly caused by an inherited flaw in the Survival Motor Neuron (SMN) gene, SMA is presently without a cure. A key reason is the lack of detailed information on how ...
Laboratories that test chemicals for neurological toxicity could reduce their use of laboratory mice and rats by replacing these animal models with tiny aquatic flatworms known as freshwater planarians.
Scientists at UC San Diego have discovered that planarians, commonly used in high-school biology labs to study regeneration and the primitive nervous system, are actually quite sophisticated when it comes to modeling the response of the developing human nervous system to potentially toxic chemicals.
The researchers published their findings in the current issue of the journal ...
Tamper-resistant formulations of drugs will not solve the problems of opioid addiction and overdose, argues a commentary in CMAJ (Canadian Medical Association Journal).
Governments in Canada and the United States are promoting tamper-resistant drugs, which are more difficult to crush, snort or inject, to prevent addiction and other harms. Opioid users may tamper with prescribed tablets, capsules or patches for a faster "high."
"Misuse and diversion of opioids is a complex problem that requires a comprehensive solution; simply substituting one formulation for another ...
At the Association for Computing Machinery's Programming Language Design and Implementation this month, MIT researchers presented a new system that repairs dangerous software bugs by automatically importing functionality from other, more secure applications.
Remarkably, the system, dubbed CodePhage, doesn't require access to the source code of the applications whose functionality it's borrowing. Instead, it analyzes the applications' execution and characterizes the types of security checks they perform. As a consequence, it can import checks from applications written ...
WASHINGTON - Tremendous variability in wait times for health care appointments exists throughout the U.S., ranging from same day service to several months, says a new report from the Institute of Medicine. However, there is currently an opportunity to develop "systems-based approaches" -- similar to systems-based engineering approaches applied successfully in industries beyond health care -- that aim to provide immediate engagement of a patient's concern at the point of initial contact and can be used in in-person appointments as well as alternatives such as team-based ...
MADISON - A group of University of Wisconsin-Madison engineers and a collaborator from China have developed a nanogenerator that harvests energy from a car's rolling tire friction.
An innovative method of reusing energy, the nanogenerator ultimately could provide automobile manufacturers a new way to squeeze greater efficiency out of their vehicles.
The researchers reported their development, which is the first of its kind, in a paper published May 6, 2015, in the journal Nano Energy.
Xudong Wang, the Harvey D. Spangler fellow and an associate professor of materials ...
NEW YORK -- June 29, 2015 /Press Release/ -- Scientists from the Icahn School of Medicine at Mount Sinai have developed a new approach to build nearly complete genomes by combining high-throughput DNA sequencing with genome mapping. The methodology enabled researchers to detect complex forms of genomic variation, critically important for their association with human disease, but previously difficult to detect. The study was published today in Nature Methods, and is a collaboration with scientists at European Molecular Biology Lab, Weill Cornell Medical College, Cold Spring ...
Will next Saturday's Tour de France prologue in Utrecht get the winner it deserves? New aerodynamic research at Eindhoven University of Technology (TU/e) shows that riders in a time trial can save vital seconds by riding closer to the following team car. Over a short distance like the prologue of the Tour de France, that can save as much as 6 seconds: enough to make the difference between winning and losing. On longer time trials and events like world championships, the effect can even add up to tens of seconds. Which is why aerodynamics professor Bert Blocken is advising ...
